Journal of Clinical Oncology
Articles in this Issue
Real-world evaluation of treatment patterns and clinical outcomes among patients with primary mediastinal large B-cell lymphoma treated with brentuximab vedotin (BV)–based treatment options in China.
e19058 Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare, aggressive and clinically heterogeneous lymphoma with unique clinical, pat...
Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.
2519 Background: Tumor heterogeneity and low mutational burden limits the availability of effective immunotherapy targets. Aberrant RNA-splicing (neojunct...
Prognostic impact of sarcopenia and surgical timing in locally advanced esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy: TIMES study.
e16137 Background: Optimal timing for surgery after neoadjuvant chemoradiotherapy (NCRT) remains controversial, necessitating reliable preoperative indica...
Exploring the efficacy of GEMOX-lenvatinib after GEMOX ± sorafenib failure in unresectable fibrolamellar carcinoma.
e16267 Background: Fibrolamellar Carcinoma (FLC) is a rare, aggressive primary liver cancer affecting children and young adults. It is often diagnosed at...
Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit.
3558 Background: Gene fusions are rare genomic events in colorectal cancer (CRC) and can co-occur with other potentially actionable alterations. Navigatin...
Impact of radiomic features on prediction of progression-free survival in patients with non-small cell lung cancer stage IV.
e20524 Background: Despite advancements in understanding NSCLC, survival rates for stage IV patients remain low, and predicting disease progression at tre...
Analysis of atezolizumab immune-related adverse events based on the US FAERS database.
e24102 Background: Objective To introduce the risk of adverse events (AE) of atezolizumab and provide a reference for the safe clinical application of thi...
Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).
8063 Background: Although neoadjuvant immune checkpoint inhibitors (ICIs) combined with chemotherapy is the current standard of care for resectable NSCLC,...
Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guérin (BCG) in the United States through a recurrence algorithm: A SEER-Medicare study.
4601 Background: Assessing bladder recurrences in real-world setting can be challenging due to the lack of readily availab...
Novel multi-omic biosignature for identification of early-stage invasive breast cancer patients who do and do not benefit from adjuvant radiation treatment after breast conservation surgery.
e12566 Background: Adjuvant radiation therapy (RT) has been a standard component of breast conserving therapy (BCT), demonstrating a reduction in local re...
Efficacy and safety results of a first-in-class PD-1/IL-2 <sup>α-bias</sup> bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.
2502 Background: Despite great success of immunotherapy (IO) in advanced melanoma, there remains an unmet clinical need for resistant tumors. Pts with acr...
Efficacy and safety of second-line lenvatinib after progression on immunotherapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis.
e16258 Background: Immunotherapy is now the standard first-line therapy for advanced hepatocellular carcinoma (HCC). Although lenvatinib was approved for...
Incidence and survival outcomes of breast cancer subtypes in the United States.
e13184 Background: While the overall incidence of breast cancer (BC) in the US has been increasing, the epidemiology and outcomes of specific histological...
Multidisciplinary and multi-institutional cancer symptom management strategies in the Veterans Affairs: A mixed methods study.
12076 Background: Effective symptom management in patients undergoing cancer treatment improves quality of life and overall survival. Yet, variability per...
Real-world evaluation of a “hyperselection” predictive biomarker for anti-EGFR therapy benefit in patients with RAS/RAF wild-type, MMRp/MSS mCRC.
e15591 Background: The PARADIGM trial showed an OS benefit to 1L doublet chemo+anti-EGFR vs doublet+anti-VEGF treatment (tx) in patients with RAS wild-typ...
Toxicity profile of enfortumab vedotin with or without pembrolizumab in patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
e16567 Background: Enfortumab Vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has recently been integrated into the treatment landscape for m...
Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study.
4558 Background: In the past 7 years, 4 immuno-oncology (IO) based combinations have been approved for mRCC. However, QOL data on these combinations are l...
Real-world analysis of thromboembolism in SAVED/IMPEDE risk-stratified newly diagnosed multiple myeloma (NDMM).
7561 Background: The rate of thromboembolic (TE) events in NDMM patients (pts) treated with IMiD-containing regimens ranges from 11-19%, with venous event...
Impact of multimodal, multidisciplinary care on clinical outcomes in patients with breast cancer and leptomeningeal carcinomatosis.
e13043 Background: Leptomeningeal carcinomatosis (LMC) is a rare consequence of metastatic breast cancer (MBC) with a dismal prognosis, with a historical...
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
3008 Background: Numerous studies have demonstrated the prognostic value of ctDNA analysis after neoadjuvant chemotherapy for early-stage high-risk breast...
Adherence to cervical cancer screening among sexual and racial/ethnic minorities during the COVID-19 pandemic in the United States.
e22530 Background: Sexual and racial minorities face barriers to accessing health care. While the association of sexual orientation and racial identity wi...
Optimal maintenance therapy strategy for metastatic nasopharyngeal carcinoma: Insights from a cohort study in an endemic region.
6041 Background: Managing metastatic nasopharyngeal carcinoma (mNPC) remains challenging due to its high incidence and mortality rates. While maintenance...
CARE-AI: Cancer assessment risk estimation using artificial intelligence.
e13618 Background: Access to genetic testing for detecting hereditary cancer is limited, and conventional methods for selecting candidates are often impre...
The impact of racial and socioeconomic disparities on radiation therapy delays in breast cancer patients: A National Cancer Database analysis.
540 Background: Despite advancements in breast cancer (BC) treatment, significant disparities in outcomes persist in the United States. Timely initiation...
Safety profile and risk factors associated with incadronate disodium treatment in breast cancer patients with bone metastases: A retrospective analysis.
e13113 Background: Bone metastases are frequent in advanced breast cancer, often leading to skeletal-related events (SREs). Bisphosphonates like incadrona...